Search

Your search keyword '"Romeo, Stefano"' showing total 901 results

Search Constraints

Start Over You searched for: Author "Romeo, Stefano" Remove constraint Author: "Romeo, Stefano"
901 results on '"Romeo, Stefano"'

Search Results

1. Design, Fabrication, and Characterization of a User-Friendly Microfluidic Device for Studying Liver Zonation-on-Chip (ZoC)

2. A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease

4. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women

5. Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI

6. Author Correction: Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women

8. Neural Network Training with Highly Incomplete Datasets

10. Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models

14. Extracting quantitative biological information from brightfield cell images using deep learning

17. A global research priority agenda to advance public health responses to fatty liver disease

18. Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis

19. Review article: the emerging role of genetics in precision medicine for patients with non‐alcoholic steatohepatitis

22. Simulation design for forthcoming high quality plasma wakefield acceleration experiment in linear regime at SPARC_LAB

23. Rare ATG7 genetic variants predispose patients to severe fatty liver disease

26. PSD3 downregulation confers protection against fatty liver disease

29. The first MASH drug therapy on the horizon: Current perspectives of resmetirom.

31. PPP1R3B rs4240624 genotype is associated with gallstones and with significant changes in bile lipidome

32. Mitochondrial amidoxime‐reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome

33. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease

34. Corrigendum to “SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease” [J Hepatol 80 (2024) 10-19]

35. IL32 downregulation lowers triglycerides and type I collagen in di-lineage human primary liver organoids

36. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

38. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

41. Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population.

42. Risk of major adverse liver outcomes among first‐degree relatives of individuals with MASLD.

44. Predictors of controlled attenuation parameter in metabolic dysfunction

47. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis

48. Effects of C-Peptide Replacement Therapy on Bone Microarchitecture Parameters in Streptozotocin-Diabetic Rats

50. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Catalog

Books, media, physical & digital resources